Achilles Therapeutics plc
ACHL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4,731 | $3,688 | $3,288 | $778 |
| Gross Profit | -$4,731 | -$3,688 | -$3,288 | -$778 |
| % Margin | – | – | – | – |
| R&D Expenses | $67,646 | $57,263 | $42,224 | $22,629 |
| G&A Expenses | $17,009 | $21,120 | $21,971 | $11,098 |
| SG&A Expenses | $12,344 | $21,120 | $21,971 | $11,098 |
| Sales & Mktg Exp. | -$4,665 | $0 | $0 | $0 |
| Other Operating Expenses | -$9,400 | $7,318 | $3,133 | $531 |
| Operating Expenses | $75,255 | $78,383 | $64,195 | $33,727 |
| Operating Income | -$75,255 | -$78,383 | -$64,195 | -$33,727 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6,081 | $7,318 | $3,133 | $531 |
| Pre-Tax Income | -$69,174 | -$71,065 | -$61,062 | -$33,196 |
| Tax Expense | $491 | $111 | $37 | $3 |
| Net Income | -$69,665 | -$71,176 | -$61,099 | -$33,199 |
| % Margin | – | – | – | – |
| EPS | -1.74 | -1.82 | -2.13 | -0.82 |
| % Growth | 4.4% | 14.6% | -159.8% | – |
| EPS Diluted | -1.74 | -1.82 | -2.13 | -0.82 |
| Weighted Avg Shares Out | 39,973 | 39,140 | 28,655 | 40,622 |
| Weighted Avg Shares Out Dil | 39,973 | 39,140 | 28,655 | 40,622 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4,731 | $3,688 | $3,288 | $778 |
| EBITDA | -$70,442 | -$67,333 | -$60,807 | -$32,955 |
| % Margin | – | – | – | – |